SOURCE: Biophan Technologies, Inc.

March 14, 2008 07:00 ET

Biophan Announces Appointment of John H. Bowers as Senior Technologist for Myotech

PITTSFORD, NY--(Marketwire - March 14, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced the appointment of John H. Bowers, as Senior Technologist for Myotech, LLC, effective immediately. Myotech is a majority-owned subsidiary of Biophan Technologies, Inc.

Mr. Bowers has thirty-five years of electrical engineering and applied research experience, 21 years of which have been spent in high-level consulting. For the past ten years, Mr. Bowers has been a Principal with Teknokon LLC, where he has consulted on the development of prototype products and processes for various technology companies. In addition, he has provided expert opinions to legal firms related to patent issues.

From 1991 to 1997, he worked for Checkpoint Systems, Inc., first as Director of Technology Development, when Checkpoint's RF EAS (electronic article surveillance) technology became a market leader and then as Director of RFID Development, where he spearheaded the development of the system for Checkpoint's library customers.

From 1980 to 1991, Mr. Bowers was Principal and Technical Manager for PA Consulting Group which provided technical guidance and training, project management, and quality control for a variety of electronic consulting assignments, primarily in the medical industry. He began his career with Princeton Electronic Products, Inc. as a Development Engineer.

James Goldberg, President of Myotech, said, "I am delighted with the addition of Mr. Bowers to our technical team. He is a master at solving complex technical and interdisciplinary challenges involving electromechanical, electronics, and software issues. His diverse industry experience, including major biomedical device products, is an invaluable augmentation to the team that will have responsibility for rapidly commercializing the first Myotech system intended for cardiac surgery indications."

The Myotech Circulatory Support System (CSS) consists of an external drive unit and flexible polymer cup that slips over the heart and is designed to provide the energy that enables the heart to restore normal blood flow. It is designed to be deployed quickly for use in resuscitation and insufficient cardiac output indications. Since it will have no contact with circulating blood, the Myotech CSS is expected to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which is intended to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contacts:
    Carolyn Hotchkiss
    Biophan Technologies, Inc.
    Communications Manager
    (585) 267-4800
    Email Contact